

Financial Tear Sheet

Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Stock Quote


ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$11.15
Change (%)	0.00 (0.00%)
Volume	0

Data as of June 22, 2017 4:00 p.m. ET

Minimum 20 minute delay

[Refresh quote](#)

Stock Chart



Press Releases

June 01, 2017

Aduro Biotech Announces FDA Clearance of Investigational New Drug Application to Evaluate the Combination of ADU-S100 with PDR001 for the Treatment of Solid Tumors and Lymphomas

May 26, 2017

Aduro Biotech to Host and Webcast an Investor Event in Conjunction with the 2017 ASCO Annual Meeting

Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters